

Andreas Wicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3796181/publications.pdf>

Version: 2024-02-01

39
papers

3,743
citations

331670

21
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

7728
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. <i>European Urology Oncology</i> , 2022, , .	5.4	10
2	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. <i>Cancer Cell</i> , 2021, 39, 288-293.	16.8	71
3	Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. <i>Oncimmunology</i> , 2020, 9, 1748981.	4.6	19
4	Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms. <i>Laboratory Investigation</i> , 2020, 100, 1475-1484.	3.7	15
5	Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. <i>Journal of Geriatric Oncology</i> , 2019, 10, 304-310.	1.0	20
6	Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. <i>American Journal of Pathology</i> , 2018, 188, 1276-1288.	3.8	28
7	First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). <i>European Journal of Cancer</i> , 2018, 96, 6-16.	2.8	51
8	Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?. <i>Seminars in Cancer Biology</i> , 2018, 48, 70-77.	9.6	28
9	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	7.0	92
10	Towards More Structure: Comparing TNM Staging Completeness and Processing Time of Text-Based Reports versus Fully Segmented and Annotated PET/CT Data of Non-Small-Cell Lung Cancer. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-10.	0.8	2
11	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89.	3.0	18
12	Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. <i>Neoplasia</i> , 2017, 19, 196-206.	5.3	22
13	Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. <i>Blood</i> , 2017, 129, 879-882.	1.4	44
14	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. <i>Oncotarget</i> , 2017, 8, 69204-69218.	1.8	21
15	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study. , 2016, 4, 13.		162
16	SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. <i>BMC Cancer</i> , 2016, 16, 780.	2.6	41
17	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. <i>Physiological Reviews</i> , 2016, 96, 805-829.	28.8	49
18	Grover-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27

#	ARTICLE	IF	CITATIONS
19	Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. <i>Journal of Drug Targeting</i> , 2016, 24, 80-89.	4.4	17
20	AKT-ions with a TWIST between EMT and MET. <i>Oncotarget</i> , 2016, 7, 62767-62777.	1.8	71
21	Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. <i>International Journal of Pharmaceutics</i> , 2015, 484, 8-15.	5.2	38
22	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv171-djv171.	6.3	78
23	Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 1-4.	2.1	23
24	Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. <i>Journal of Controlled Release</i> , 2015, 200, 138-157.	9.9	1,477
25	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
26	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. <i>Cancer Research</i> , 2015, 75, 2664-2664.	0.9	3
27	Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 181-186.	0.5	1
28	Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. <i>EJNMMI Research</i> , 2014, 4, 9.	2.5	4
29	Pre-Existing Antihypertensive Treatment Predicts Early Increase in Blood Pressure during Bevacizumab Therapy: The Prospective AVALUE Cohort Study. <i>Oncology Research and Treatment</i> , 2014, 37, 230-236.	1.2	14
30	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , 2014, 124, 1782-1782.	1.4	1
31	Targeted therapies in breast cancer. <i>Swiss Medical Weekly</i> , 2012, 142, w13550.	1.6	9
32	Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , The, 2012, 13, 1234-1241.	10.7	208
33	Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth. <i>Clinical Cancer Research</i> , 2012, 18, 454-464.	7.0	91
34	Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. <i>Journal of Drug Targeting</i> , 2012, 20, 422-432.	4.4	47
35	Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1059-1067.	5.0	141
36	Kras in metastatic colorectal cancer. <i>Swiss Medical Weekly</i> , 2010, 140, w13112.	1.6	17

#	ARTICLE	IF	CITATIONS
37	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO Journal, 2008, 27, 2603-2615.	7.8	167
38	[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma. Clinical Cancer Research, 2007, 13, 3696-3705.	7.0	92
39	Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell, 2006, 9, 261-272.	16.8	520